Dopamine Receptor Homooligomers and Heterooligomers in Schizophrenia

Acetylcholine-Dopamine Interactions in the Pathophysiology and Treatment of CNS Disorders

(2010) Deranda B Lester et al.   CNS Neuroscience & Therapeutics

All Roads to Schizophrenia Lead to Dopamine Supersensitivity and Elevated Dopamine D2High Receptors

(2010) Philip Seeman   CNS Neuroscience & Therapeutics

An inverse relationship between cortisol and BDNF levels in schizophrenia: Data from human postmortem and animal studies

(2010) George Issa et al.   NEUROBIOLOGY OF DISEASE

Promoter specific alterations of brain-derived neurotrophic factor mRNA in schizophrenia

(2010) J. Wong et al.   NEUROSCIENCE

Switching schizophrenia patients from typical neuroleptics to aripiprazole: Effects on working memory dependent functional activation

(2010) Florian Schlagenhauf et al.   SCHIZOPHRENIA RESEARCH

Decreased BDNF in patients with antipsychotic naïve first episode schizophrenia

(2010) Ripu D. Jindal et al.   SCHIZOPHRENIA RESEARCH

Cocaine self-administration markedly increases dopamine D2receptor negative cooperativity for dopamine binding: A receptor dimer-based analysis

(2010) Rafael Franco et al.   SYNAPSE

The Effect of Antipsychotics on the High-Affinity State of D2 and D3 Receptors

(2009) Ariel Graff-Guerrero et al.   ARCHIVES OF GENERAL PSYCHIATRY

Baseline and Amphetamine-Stimulated Dopamine Activity Are Related in Drug-Naïve Schizophrenic Subjects

(2009) Anissa Abi-Dargham et al.   BIOLOGICAL PSYCHIATRY

Marked changes in signal transduction upon heteromerization of dopamine D1 and histamine H3 receptors

(2009) Carla Ferrada et al.   BRITISH JOURNAL OF PHARMACOLOGY

Molecular integration via allosteric interactions in receptor heteromers. A working hypothesis

(2009) Kjell Fuxe et al.   CURRENT OPINION IN PHARMACOLOGY

Dopamine D2–D3 receptor heteromers: pharmacological properties and therapeutic significance

(2009) Roberto Maggio et al.   CURRENT OPINION IN PHARMACOLOGY

Heteromerization of dopamine D2 receptors with dopamine D1 or D5 receptors generates intracellular calcium signaling by different mechanisms

(2009) Ahmed Hasbi et al.   CURRENT OPINION IN PHARMACOLOGY

Metabotropic glutamate type 5, dopamine D2and adenosine A2areceptors form higher-order oligomers in living cells

(2009) Nuria Cabello et al.   JOURNAL OF NEUROCHEMISTRY

Co-operativity in agonist binding at the D2dopamine receptor: evidence from agonist dissociation kinetics

(2009) Elodie Kara et al.   JOURNAL OF NEUROCHEMISTRY

WS-50030 [7- -1,3-benzoxazol-2(3H)-one]: A Novel Dopamine D2 Receptor Partial Agonist/Serotonin Reuptake Inhibitor with Preclinical Antipsychotic-Like and Antidepressant-Like Activity

(2009) J. A. Brennan et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Calcium Signaling by Dopamine D5 Receptor and D5-D2 Receptor Hetero-Oligomers Occurs by a Mechanism Distinct from That for Dopamine D1-D2 Receptor Hetero-Oligomers

(2009) C. H. So et al.   MOLECULAR PHARMACOLOGY

Activation of calcium/calmodulin-dependent protein kinase IIα in the striatum by the heteromeric D1-D2 dopamine receptor complex

(2009) J. Ng et al.   NEUROSCIENCE

Calcium signaling cascade links dopamine D1–D2 receptor heteromer to striatal BDNF production and neuronal growth

(2009) Ahmed Hasbi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Evaluation of the antipsychotic effect of bi-acetylated l-stepholidine (l-SPD-A), a novel dopamine and serotonin receptor dual ligand

(2009) Yang Guo et al.   SCHIZOPHRENIA RESEARCH

Glutamate agonist LY404,039 for treating schizophrenia has affinity for the dopamine D2Highreceptor

(2009) Philip Seeman et al.   SYNAPSE

Glutamate agonists for treating schizophrenia have affinity for dopamine D2Highand D3 receptors

(2009) Philip Seeman et al.   SYNAPSE

Receptor–receptor interactions within receptor mosaics. Impact on neuropsychopharmacology

(2008) K. Fuxe et al.   BRAIN RESEARCH REVIEWS

The role of D1–D2 receptor hetero-dimerization in the mechanism of action of clozapine

(2008) Agata Faron-Górecka et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

Identification of Dopamine D1–D3Receptor Heteromers

(2008) Daniel Marcellino et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Opposing Patterns of Signaling Activation in Dopamine D1 and D2 Receptor-Expressing Striatal Neurons in Response to Cocaine and Haloperidol

(2008) J. Bertran-Gonzalez et al.   JOURNAL OF NEUROSCIENCE

Reciprocal Regulation of Dopamine D1 and D3 Receptor Function and Trafficking by Heterodimerization

(2008) C. Fiorentini et al.   MOLECULAR PHARMACOLOGY

Antagonistic cannabinoid CB1/dopamine D2 receptor interactions in striatal CB1/D2 heteromers. A combined neurochemical and behavioral analysis

(2008) Daniel Marcellino et al.   NEUROPHARMACOLOGY

Interactions between histamine H3 and dopamine D2 receptors and the implications for striatal function

(2008) Carla Ferrada et al.   NEUROPHARMACOLOGY

The Dopamine D2 Receptors in High-Affinity State and D3 Receptors in Schizophrenia: A Clinical [11C]-(+)-PHNO PET Study

(2008) Ariel Graff-Guerrero et al.   NEUROPSYCHOPHARMACOLOGY

Fronto-striatal hypoactivation during correct information retrieval in patients with schizophrenia: An fMRI study

(2008) K. Koch et al.   NEUROSCIENCE

The antipsychotic potential of l-stepholidine—a naturally occurring dopamine receptor D1 agonist and D2 antagonist

(2008) Sridhar Natesan et al.   PSYCHOPHARMACOLOGY

Glutamate agonists for schizophrenia stimulate dopamine D2High receptors

(2008) Philip Seeman   SCHIZOPHRENIA RESEARCH

The efficacy of aripiprazole in the treatment of multiple symptom domains in patients with acute schizophrenia: A pooled analysis of data from the pivotal trials

(2008) John M. Kane et al.   SCHIZOPHRENIA RESEARCH